Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Here’s Why Eli Lilly (LLY) Traded Down in Q4
Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...
FierceBiotech3h
Eli Lilly’s next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
BioPharma Dive3h
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Is Now The Time To Put Eli Lilly (NYSE:LLY) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...
AOL18d
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan ... The Motley Fool Stock Advisor analyst team just identified what they believe ...